Introduction
In chronic myeloid leukaemia (CML), the t(9;22)(q34;q11) translocation creates the fusion gene BCR-ABL. BCR-ABL protein is central to CML pathogenesis, and leukaemia-specific amino acid sequences span the fusion junction. There are two alternative junctional sequences, known as e13a2 and e14a2 (or b2a2 and b3a2). At the e14a2 junction, a novel amino acid (lysine) is created, which is not present in wild type BCR or ABL. 1 The e14a2 junctional sequences KQSSKALQR and GFKQSSKAL bind well to HLA-A3/A11 and HLA-B8 respectively. 2 These peptides induce CD8 þ T cell responses, which may kill HLA-matched CML cells, suggesting that CML cells may express these peptides (reviewed in 1 ) . Using tandem nanospray mass spectrometry, we have confirmed that HLA-A3 þ CML cells express HLA-associated KQSSKALQR on the cell surface, 3 and also that a single unpublished HLA-B8 þ case expressed GFKQSSKAL. Proteosomal digestion experiments have demonstrated that KQSSKALQR but not GFKQSSKAL is naturally processed by the proteasome and the immunoproteasome. 4 CD8 þ T cells directed against KQSSKALQR and GFKQSSKAL may circulate in HLA-A3 þ and HLA-B8 þ CML patients respectively, 5 in line with similar studies after allogeneic stem cell transplantation (SCT) 6 and for other antigens. 7 Taken together, these data suggest that vaccination with e14a2 BCR-ABL junctional peptides could benefit e14a2 CML patients.
Here we report a phase I/II clinical study of BCR-ABL peptide vaccination in e14a2 transcript positive CML patients, known by the acronym EPIC (Evaluation of Peptide Immunisation in CML).
To maximise CD4
þ help, we included BCR-ABL peptides covalently linked to the peptide sequence PADRE (pan DR epitope). 8 PADRE is a 15-mer which includes 4 non-natural amino acids, which binds well to 15 of the 16 most common HLA-DR types. 9 In vitro, PADRE induces CD4 þ T cell responses in virtually all individuals. 8 It has been used as an adjuvant in vaccination studies in cervical carcinoma, 10 malaria, 11 CMV, 12 polio 13 and Alzheimers disease. 14 
Patients and methods

Patients and blood samples
The protocol was approved by our institutional ethics committee and the Central Institutional Review Board of Cancer Research UK. Entrants fulfilled all of the following: aged 18 or over, e14a2 BCR-ABL transcript positive CML in first chronic phase, at least 6 months treatment with imatinib at a stable dose of at least 400 mg daily, and in a complete haematological response (defined as a normal full blood count with no hepatosplenomegaly). Entry was not restricted by level of cytogenetic response or by HLA type.
Vaccine
Each patient received a cocktail of 3 peptides spanning the e14a2 fusion junction. The sequences (Table 1) depended on the patient's HLA type (Table 2) . HLA-A3 and -A11 positive patients received the 9-mer peptide KQSSKALQR (peptide A). Patients that were HLA-A3 and -A11 negative received the peptide sequence GFKQSSKAL (peptide D) which binds to HLA-B8 2 and to which T cell responses have been shown in post allograft HLA-A2 positive CML patients. 6 In order to augment CD4 þ responses, each patient also received the same sequence linked to the 15-mer peptide sequence PADRE. The resultant PADRElinked sequences are peptides B and E below. Finally, all patients received peptide C, which comprises PADRE linked to a 13-mer 'consensus' peptide spanning the e14a2 BCR-ABL fusion junction and including 3 junctional peptides known to bind HLA-A3, B8 and A2. All peptides were synthesised by Bachem (St Helens, Merseyside) and packaged for clinical use by Quality Control North West (Stockport, Cheshire), under Good Manufacturing Practice conditions, with at least 97.5% purity unless containing cysteine residues in which case purity was at least 95%. Stability testing during storage at À401C revealed that peptide B was unstable beyond 4 months, though the other peptides remained stable for at least 12 months.
Protocol design
The study design was of dose escalation in 4 successive cohorts of 5 patients each, receiving 100 mg, 300 mg, 600 mg or 1000 mg of each peptide in successive cohorts (cohort 4 consisted of 4 patients). All 3 peptides were combined in a single intradermal injection, 15 min after 40 mg of sargramostim (GM-CSF) was given at the same site as an adjuvant in order to enhance immune responses to the vaccine. 15, 16 Vaccination was given on days 1, 8, 15, 22, 36 and 64. Samples were collected for immunological and molecular assessment prior to each vaccination on days 1, 22 and 64, and also at days 92, 120, 148, 176 and 268.
Dendritic cell (DC) preparation
For immunological assessment, peripheral blood mononuclear cells (PBMC) were isolated using standard gradient centrifugation. Aliquots were stored at À801C until required. Dendritic cells were prepared from half of the baseline PBMC, as previously described, 17 and frozen in 85% foetal calf serum (Biowest, Nuaille, France), 10% DMSO (BDH, Leicestershire) and 5% glucose (45% w/v; Sigma, Dorset, UK) on day 6. DC were thawed as required, cultured in complete media overnight and then matured with 10 ng/ml of TNF-a (Peprotech EC, London, UK) for 24 h, before being used as antigen presenting cells (APC).
Assessment of T cell responses to the vaccine
T cell responses were assessed by IL-5 and interferon (IFN)-g enzyme-linked immunospot (ELISPOT) (Diaclone, France). Responses were assessed in both unstimulated and stimulated cultures to PADRE, the 9-mer used for vaccination (peptide A or D; see Table 1 ) and the e14a2 junctional 18-mer ATGFKQSS-KALQRPVASD. For unstimulated cultures, thawed PBMC were rested for 4-6 h then challenged in the ELISPOT plates with 10 mg/ml of the relevant peptide. For stimulated cultures, the remaining cells were stimulated with DC and/or autologous irradiated PBMC pulsed with the relevant peptide (10 mg/ml). IL-7 (1 ng/ml), IL-2 (50 U/ml; both R & D Systems, Abingdon) and IL-12 (2 ng/ml; Peprotec) were added to the cultures. Cells were tested after 7-10 days by ELISPOT for specific responses to PADRE and the e14a2 peptides. When cell numbers permitted, cells from stimulated cultures were also tested by flow cytometry for the secretion of IFN-g.
ELISPOT assay
In unstimulated cultures, T cell responses were assessed by incubating 5-10 Â 10 4 PBMC/well overnight with either PADRE or the e14a2 peptides. As control, PBMC were cultured without peptide and/or with the irrelevant peptides ILRGSVAHK (HLA-A3 associated influenza A NP (265-273) peptide for HLA-A3 negative patients) and NKRYFKLSHLQMHSR (HLA-DR4 associated peptide from residues 331-345 of the Wilms tumour antigen WT1, for HLA-DR4 negative patients). No differences in responses were observed between these control cultures without peptide or with an irrelevant peptide. For stimulated cultures, 5 Â 10 4 PBMC/well were plated with autologous irradiated PBMC as APC, with and without the peptide used for the preceding stimulation. Therefore, in all ELISPOT assays negative controls were used (culture with unpulsed PBMC). Table 1 Sequences of peptides used for vaccination Table 1 for definition.
All ELISPOT assays were performed in triplicate or quadruplicate. A significant result was defined conventionally, i.e. where the counts were both: 10 or more spots higher and also at least double that of the background. In addition, the proportion of IFN-g producing cells was compared using unpaired Student's t test. Results are presented as the number of specific spots (the difference in spots with and without peptide).
IFN-g secretion measurement by flow cytometry
These experiments were performed using an IFN-g secretion/ capture assay kit (Miltenyi, Surrey) according to the manufacturer's instructions. Samples were co-stained with fluorochrome-labelled antibodies to CD4 and CD8 (Serotec, Oxford), thus permitting determination of the IFN-g producing subset, after exclusion of non-viable cells using propidium iodide 0.5 mg/ml prior to analysis. As described previously, 18 a difference of 0.20 points in IFN-g producing cells in the cultures with and without peptide was considered significant. In all significant cases (i.e. where IFN-g was produced specifically to the peptide), the number of peptide specific IFN-g producing cells was at least double that of the control.
When CD45RO staining was performed, cells were incubated with Cy5 conjugated anti-CD45RO antibody (Dako, Ely) for 20 min on ice and then washed twice, prior to the addition of the catch reagent of the IFN-g secretion/capture assay kit.
BCR-ABL mRNA quantitation
The BCR-ABL mRNA transcript level was measured by quantitative real time polymerase chain reaction (QRT-PCR) as previously described, 19 using ABL as the control gene, in line with recent recommendations. 20 For nested PCR studies, cDNA was amplified as described previously. 21 
Cytogenetic studies
Marrow metaphase cytogenetics were assessed by standard techniques. 19 Complete cytogenetic remission (CCR) is defined as absence of Philadelphia chromosome positive (Ph þ ) metaphases and/or a BCR-ABL/ABL transcript ratio of less than 1%. We have previously demonstrated that a BCR-ABL/ABL transcript ratio of less than 1% correlates with CCR. 19 Major cytogenetic response is defined as 0-34% Ph þ metaphases and cytogenetic non-response as 95% or greater Ph þ metaphases.
Results
Clinical details and HLA types for all 19 entrants are given in Table 2 . All cases had been stable on the same dose of imatinib for at least 8 months. In 16 cases this was 400 mg daily; in 3 cases this was 600 mg daily, because of earlier suboptimal response at 400 mg daily. At trial entry, 14 patients had major cytogenetic responses, and 5 had cytogenetic non-response.
Toxicity
No problems were seen after the first vaccination in any patient.
Mild local skin reactions were seen following the second and subsequent vaccinations in all patients, with appearances compatible with delayed type hypersensitivity. A single patient developed muscular pains, tachycardia, fever and facial swelling about 2 h after her third (Day 15) vaccination (case 19 in Table 2 ). It is likely that this was anaphylaxis to sargramostim; she recovered fully within about 24 h. She did not receive the final 3 vaccinations, but was assessed immunologically and molecularly on schedule.
Immunological responses
Responses to PADRE by ELISPOT. Since PADRE is a novel antigen, the immune response to it will assess the 'visibility' of the vaccination strategy. Responses in unstimulated cultures were detected in 4 of 19 patients (Cases 6, 7, 11 and 15; data not shown). In stimulated cultures, responses were detected in all 19 patients, presented in Figure 1 as numbers of specific spots in ELISPOT, stratified by peptide dose. No responses were detectable in any pre-vaccination sample. The responses typically peaked at the end of vaccination (day 64 or 92), and were detectable up to day 176 but not at day 268. In all 11 patients where flow cytometric IFN-g secretion was feasible, the IFN-g producing T cell subset was CD4 þ (Table 3 ). These data indicate that the immune system recognises the vaccination peptides, and can produce durable immune responses for several months.
Responses to e14a2 peptides. PBMC were tested against the 9-mer peptide used in vaccination (either peptide A or D of Table 1 ). IFN-g ELISPOT responses to the 9-mer peptide were detected in unstimulated PBMC in one patient (Case 2; data not shown). In stimulated cultures, specific IFN-g ELISPOT responses were detected in 11 of the 19 patients (Figure 2, panel  A-D) . In all but one patient (case 12), this response was only detectable following vaccination. These responses peaked between day 64 and 92, but disappeared by day 148 in all patients except case 12. Flow cytometry analysis demonstrated that in 6 assessable cases, IFN-g was produced by CD8 þ T cells when cultured with peptide A or D (Table 3) . No responses in IL-5 ELISPOT were seen for any case in either unstimulated or stimulated cultures, ruling out the presence of a Tc2 response.
Responses were also assessed to the 18-mer peptide ATGFKQSSKALQRPVASD. Specific IFN-g ELISPOT responses were detectable in unstimulated cultures in 4 of 19 patients (Cases 2, 7, 8 and 12; data not shown). In stimulated cultures, specific PBMC were detected by IFN-g ELISPOT in 14 of 19 patients (Figure 3 ). In 13 patients, this response was only detectable following vaccination, and flow cytometric IFN-g secretion studies revealed the IFN-g producing T cell subset to be CD4 þ (Table 3) . Like those to the 9-mer e14a2 sequences, responses were transient and peaked between day 64 and 92. Again, no responses were seen in IL-5 ELISPOT for any case in either unstimulated or stimulated cultures, ruling out the presence of a Th2 response. The data in Figure 2 show no evidence of an immunological dose response effect between the 4 cohorts.
CD45RO staining was carried out to determine the memory status of IFN-g-producing cells. Samples of CD8 þ IFN-g þ cells were studied in 4 patients, and of CD4 þ IFN-g þ cells in a further 4 patients. In all 8 samples tested, the IFN-g producing population was CD45RO þ (data not shown), indicating that the anti-e14a2 T cell populations have a memory phenotype. Figure 3a shows the complete BCR-ABL/ABL transcript ratios for all 19 patients, including all data available prior to vaccination since commencement of imatinib. Figure 3b depicts serial BCR-ABL transcript levels to a maximum of 18 months after commencing vaccination. No evidence of a molecular dose response effect is seen across the 4 dose cohorts. A molecular response to vaccination was defined as a fall in the BCR-ABL/ABL transcript ratio of at least 1.0 log with no subsequent rise in the 12-15 months following commencement of vaccination (i.e. 10-13 months following completion of vaccination). Six cases had no molecular response to Figure 1 T-cell responses to PADRE. The dotted line represents the upper limit of negativity. Any point above this line indicates a statistically significant production of IFN-g compared to its respective control, with a difference between test and control of at least 10 spots (the detection limit of the assay) and where the background (control well) number of spots is below 20. vaccination. Two of these were censored at 9 and 12 months respectively because they received allogeneic SCT or dasatinib respectively. These 6 non-responders included all 5 cytogenetic non-responders to imatinib at trial entry (Cases 5, 6, 8, 13 and 15). All 13 molecular responders were in major cytogenetic response at trial entry. In 8 of these, transcript levels were still falling at 12 months post entry, suggesting a delayed benefit of vaccination. Nine cases were molecularly assessable at 18 months post trial entry, and in 3 of these the transcript level rose between 15 and 18 months. Overall, only one case became BCR-ABL negative by nested PCR.
Molecular responses BCR-ABL transcript level following vaccination.
Correlation between anti-BCR-ABL immunity and decrease in BCR-ABL transcripts. To determine whether an immune response to BCR-ABL correlated with an effect on BCR-ABL transcripts, the transcript levels at baseline were compared with the transcript level 1 month after the latest detection of an anti-BCR-ABL immune response. The data are presented in Table 4 . Patients responding to both peptide A/D and the 18-mer peptide had a greater reduction in BCR-ABL transcript levels than patients who did not develop an immune response to BCR-ABL or only had responses to the 18-mer peptide (Mann-Whitney two tailed: P ¼ 0.002). This supports the view that anti-BCR-ABL T cells are likely to be involved in the clearance of CML cells in vivo.
Effect of vaccination on the underlying trend in BCR-ABL transcripts. In an attempt to address whether the drop in BCR-ABL transcripts is due to an ongoing response to imatinib, rather than vaccination, Table 5 compares the rate of change in BCR-ABL transcripts before and after vaccination, for each of the 11 assessable responding cases. In 6 of 7 cases who received imatinib for at least 12 months before trial entry, the fall in transcript was greater after vaccination than pre-vaccination. Conversely, in 3 of 4 patients who had received imatinib for less than 12 months before trial entry, the fall in transcript postvaccination was unaltered or was less than pre-vaccination.
Discussion
The present data demonstrate 3 broad findings. Firstly, our peptide vaccination strategy appears safe, with a single systemic transient adverse reaction among 111 individual vaccination episodes. These findings are in line with similar reassuring data on toxicity from two earlier studies of BCR-ABL peptide vaccination. 22, 23 Secondly, vaccination elicited T cell responses that were detectable in vitro. All patients responded to the novel antigen PADRE, and the responses typically lasted for 3-4 months beyond completion of vaccination. This demonstrates that the immune system sees the vaccination cocktail in all patients. In addition, both CD4 þ and CD8 þ responses are observed to BCR-ABL peptides, and these have a memory cell phenotype. This suggests that the vaccine induced naïve anti-e14a2 T cells to become memory cells and/or has reactivated existing antie14a2 T cells. However, the responses to BCR-ABL peptides are less prevalent and less durable than those to PADRE. Possible explanations for the disparity between the PADRE and BCR-ABL responses are that BCR-ABL may be a weak antigen, or that CML patients have developed anergy to BCR-ABL. This is an important question, since it will point the way for the future design of vaccination strategies in CML.
Thirdly, vaccination is associated with a subsequent fall in the CML disease burden. BCR-ABL transcripts were reduced to a The final column gives the BCR-ABL/ABL level 1 month after last detecting a BCR-ABL immune response, expressed as a percentage of the result at commencement of vaccination. For the last 4 cases (marked by *) where no anti-BCR-ABL immune response was detected, the BCR-ABL/ABL level at 6 months post-entry in the trial was used. There is a significant difference in the transcript reduction between patients responding to both 9-mer and 18-mer peptides compared with patients with no immune response or only responding to the 18-mer peptide (P ¼ 0.002, Mann Whitney two-tailed test).
greater degree in patients with T cells specific for both 9-mer and 18-mer BCR-ABL peptides suggesting a possible contribution of anti-BCR-ABL T cells in reducing BCR-ABL transcript levels in vivo post-vaccination. Thirteen of the 14 patients in major cytogenetic response at entry achieved a molecular response, compared with none in 5 cytogenetic non-responders. Vaccination may therefore have little role in patients with poorly controlled CML. Two groups have previously investigated BCR-ABL vaccination in CML. Cathcart and colleagues 22 treated 14 patients, only 2 of whom had received imatinib, and it was not possible to determine a relationship between clinical/molecular response and vaccination. In 10 patients with stable disease on imatinib studied by Bocchia and colleagues, 23 all showed cytogenetic improvement, and 3 of 5 patients who achieved CCR had undetectable BCR-ABL transcripts by nested PCR. In the present study, we only observed disappearance of BCR-ABL transcripts in a single case. One reason for this disparity may be that we used a stringent definition of PCR negativity, requiring at least 10 000 copies of the control gene (ABL), in line with recent recommendations. 20 An alternative explanation may be that we stopped vaccination at 64 days with no booster vaccinations beyond this. In view of the differences observed between the different studies of CML vaccination with BCR-ABL peptides, optimisation of the vaccination strategy appears to be important before embarking on larger randomised studies. In the present study, we observed detectable IFN-g production to e14a2 peptides in only 3 patients with unprimed PBMC. All of the responses discussed in detail above were only seen after stimulation, in contrast to previous studies. 22, 23 These differences are not simply explained by the different regimen of vaccination, since durable responses were seen to PADRE in all patients, some in unstimulated cultures.
Long-term molecular trends in BCR-ABL transcripts and their correlation with immune responses were not addressed in previous studies. To address this, we have followed molecular response for up to 18 months from commencement of vaccination. In patients who have received imatinib for at least 12 months and have achieved a 'plateau' of their BCR-ABL transcript level, vaccination may improve the rate of fall in BCR-ABL transcripts, and may thus decrease the leukaemia burden, particularly in cases with already well-controlled disease. In all of these patients an e14a2 immune response was also observed. This observation should be confirmed in a randomised trial with a larger set of patients.
Finally, almost all patients in major cytogenetic response at trial entry had at least a 1 log fall in BCR-ABL transcript level, though this typically takes several months to emerge. The late molecular effects of BCR-ABL peptide vaccination have not been investigated in earlier studies. This observation raises the possibility that the BCR-ABL specific T cells stimulated by the vaccine have targeted primitive Ph þ cells. It is not known whether quiescent stem cells express BCR-ABL. 24 Quiescent cells may have to come into cycle to become susceptible to immune attack by BCR-ABL specific T cells, and this may take some time. 25 Cycling Ph þ stem cells express very high levels of BCR-ABL transcripts, 26 though it is not known whether they express HLA Class I associated BCR-ABL at the cell surface, as demonstrated in leukapheresis samples from newly diagnosed CML. 3 It is therefore plausible that an immune-mediated effect on the Ph þ stem cell compartment may take several months to become detectable by standard QRT-PCR.
In summary, we present evidence that BCR-ABL peptide vaccination may induce specific T cell responses and molecular improvement in CML, especially in patients who are already responding well to imatinib. Randomised trials are now required to investigate whether peptide vaccination of imatinib responders can improve the molecular control of CML. Pre-vaccination change, the mean quarterly log change in BCR-ABL transcript over the 6 months before vaccination; post-vaccination change, mean quarterly log change in BCR-ABL transcript over the 15 months after commencement of vaccination. No result is recorded for case 16 because both pre and post changes are equal.
